Stock DRUG BRIGHT MINDS BIOSCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Bright Minds Biosciences Inc.

Equities

DRUG

CA10919W4056

Market Closed - Canadian Securities Exchange
Other stock markets
 16:48:37 16/05/2024 BST 		5-day change 1st Jan Change
1.43 CAD 0.00% Intraday chart for Bright Minds Biosciences Inc. +4.38% -32.55%
05-16 Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 CI
03-22 Bright Minds Biosciences Inc. announced that it expects to receive $0.05416 million in funding CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bright Minds Biosciences : Condensed Interim Consolidated Financial Statements For the six months ended March 31, 2024 and 2023 (Expressed in Canadian Dollars) - Form 6-K
PU
Bright Minds Biosciences : Notice of Meeting and Record Date - Form 6-K
PU
Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
CI
Bright Minds Biosciences Inc. announced that it expects to receive $0.05416 million in funding
CI
Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023
CI
Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2023
CI
Bright Minds Biosciences : Announces Closing of Non-Brokered Private Placement Fully Subscribed by Management - Form 6-K
PU
Bright Minds Biosciences Inc. announced that it has received $0.9 million in funding
CI
Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management
AQ
Bright Minds Biosciences Inc. announced that it expects to receive $0.9 million in funding
CI
Bright Minds Biosciences : Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2023 and 2022 (Expressed in Canadian Dollars) - Form 6-K
PU
Bright Minds Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023
CI
Top Midday Gainers
MT
Bright Minds Biosciences on "Positive" qEEG Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
MT
Bright Minds Biosciences Brief: Announcing "Positive" qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
MT
Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101
AQ
Bright Minds Biosciences Inc. Announces Positive qEEG (Quantitative Electroencephalogram) Data from Its First-In-Human Phase 1 Study of Lead Compound, Bmb-101
CI
Bright Minds Biosciences : Announces Positive qEEG (Quantitative Electroencephalogram) Data fromits First-in-Human Phase 1 Study of Lead Compound, BMB-101
PU
Bright Minds Biosciences Announced "Positive" Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101
MT
Bright Minds Biosciences Inc. Announces Successful Completion of its Three-Part Phase 1 Study of BMB-101
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DRUG Stock
  4. News Bright Minds Biosciences Inc.